symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
RVXCF,0.05114,0.676144,27437,13880368,0,0.05-0.2,0.0011,Resverlogix Corp.,USD,,,,Other OTC,PNK,Biotechnology,https://www.resverlogix.com,"Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.",Mr. Donald J. McCaffrey,Healthcare,CA,19,,4820 Richard Road SW,Calgary,AB,T3E 6L1,,0,https://financialmodelingprep.com/image-stock/RVXCF.png,2009-02-13,True,False,True,False,False
